Pet Diabetes Care Device Market to Reach USD 4.3 Billion by 2035

According to analysts at Vantage Market Research, the Global Pet Diabetes Care Device Market size is worth USD 2.5 Billion in 2024 and is projected to reach USD 4.3 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 7.0% from 2025 to 2035. Key trends of market include wearable glucose monitoring, AI-driven analytics, non-invasive devices, e-commerce expansion, rising pet diabetes cases, smart insulin delivery, telemedicine adoption, and increasing veterinary investments.

Market Overview

Pet owners are becoming more aware of their pets' general health, resulting in increased vigilance in spotting early indicators of diabetes. As pet humanization grows, owners are more willing to invest in sophisticated healthcare solutions like glucose monitoring devices and insulin administration systems. Furthermore, veterinarians and pet care organizations are vigorously educating pet owners about diabetes treatment, emphasizing the importance of regular checkups and at-home monitoring. This increasing awareness is raising demand for new pet diabetic treatment equipment, leading in pet diabetes care device market growth.

As awareness of pet diabetes continues to increase, it presents a significant opportunity for the pet diabetes care device market. As pet diabetes becomes more well known, more owners are identifying typical symptoms including increased thirst, frequent urination, and weight loss. Furthermore, Veterinary practitioners are learning more about diabetes in pets, which may raise understanding and acceptance of these devices, resulting in improved treatment outcomes.

TeleVet and Boehringer Ingelheim Announce Strategic Collaboration

• In March 2022, TeleVet Inc., a leading provider of technology solutions for veterinary teams that increase productivity, reduce staff burnout, and improve client experience, and Boehringer Ingelheim Animal Health USA Inc. (“Boehringer Ingelheim”), a leading global innovator of animal health products for pets, horses, and livestock, today announced a strategic collaboration to deliver innovative technology and services that will make it easier for veterinary practices to provide the best patient care while alleviating stress on their teams

Key Takeaways from the Report

• North America dominated the market with 42.50% of market share in 2024. market is driven by high prevalence rate of diabetes, increase in the number of market players and surge in the number of products available in the region.
• Based on the Animal, the Dogs category accounted for significant market share of 48.70% in 2024
• In 2024, by Device type, Insulin Delivery Devices dominated the market with significant market share of 54.3%
• Based on the Distribution Channel, the Veterinary clinics and hospitals category accounted for significant market share of 41.20% in 2024.
• Based on the Technology, the Non-Wearable technology category accounted for significant market share in 2024. This segment consists of traditional and portable diabetes management tools that require manual operation
• In 2024, by Sales model, Prescription-based dominated the market with significant market share. This segment covers diabetes management devices and medications that require veterinary approval before purchase
• Based on the Price range, the Mid-range category accounted for significant market share in 2024

Top Companies

• Abbott Laboratories Inc
• Virbac
• Medtronic Plc
• Johnson & Johnson Services Inc
• Roche Diagnostics
• Bio-Rad Laboratories
• Novo Nordisk A/S
• Zoetis Inc
• Terumo Corporation
• Eli Lily and Company
• i-SENS, Inc
• IDEXX Laboratories

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats​ 

• In November 2023, Boehringer Ingelheim, a global leader in animal health, has received marketing authorization from the European Commission for SENVELGO®, marking a significant step for the treatment of feline diabetes in Europe. Globally, SENVELGO® is the first once-daily liquid oral solution for the reduction of hyperglycemia in cats with non-insulin-dependent diabetes mellitus. This breakthrough innovation will make it easier for cat owners to fit the treatment of feline diabetes into their daily lives